Akela Pharm Announces Layoffs, Restructuring and Management Changes
TechFinance.ca News
Thursday September 3, 2009
Akela Pharma, Inc. (TSX: AKL) along with its wholly owned manufacturing subsidiary, PharmaForm, today announced a c...
[ ... to read the whole article, please Log IN or Subscribe ... ]
... ... to optimize the infrastructure required to support its PharmaForm clients.
Several of Akela's international opera...
To read this or any other article, or trial test our database, please try
our 7 days or 1 month subscription,
Click Here for Details.
Company Deals and People
|
Date |
Title |
Type |
2010/12/16 |
|
Director |
2009/9/3 |
Marcelo Omelczuk, SVP, Business and Product Development |
Management |
2009/9/3 |
Rudy Emmelot, VP, Finance |
Management |
2009/9/2 |
Gregory M. McKee, President & CEO |
Management |
2009/6/25 |
|
Director |
2009/6/25 |
|
Director |
2009/5/22 |
Akela Pharma Closes Acquisition of Nventa Biopharmaceuticals |
M&A |
2009/5/22 |
|
Director |
2008/6/26 |
|
Director |
2008/3/27 |
Akela Pharma Completes Short Form Prospectus Offering |
Financing |
2007/10/15 |
AKELA Pharma Announces US Public Offering - Abandoned 12/20/2007 |
Financing |
2007/3/3 |
Ed Margerrison, VP, Programme Management |
Management |
2007/1/26 |
|
Director |
2007/1/25 |
LAB International Completes Acquisition of PharmaForm LLC |
M&A |
2007/1/11 |
Roman Denk, VP, Corporate Support |
Management |
2005/12/13 |
LAB International Closes $12.3 Million Financing |
Financing |
2005/4/27 |
LAB International Closes US $5 Million Financing |
Financing |
2005/2/10 |
LAB International Acquires Scantox |
M&A |
2005/1/18 |
Andrew Reiter, CFO, COO |
Management |
2005/1/18 |
Hanns-Christian Palka, VP, Risk Management and Controller |
Management |
2005/1/18 |
Luc Mainville, COO |
Management |
2005/1/18 |
LAB International Raises Additional $2.4 Million |
Financing |
2004/12/30 |
LAB International Closes Private Placement |
Financing |
2004/8/26 |
Denis Pilon, COO of LAB Research's Canadian Operation |
Management |
2004/6/9 |
Taneli Jouhikainen, SVP, Corporate Development & acting CEO |
Management |
2004/1/12 |
LAB International Closes €4 Million Financing |
Financing |
2004/1/12 |
LAB International Completes Acquisition of Focus Inhalation |
M&A |
2003/12/22 |
LAB International Completes Financing |
Financing |
2003/10/2 |
Yves Cornellier, SVP, Business Development |
Management |
2003/10/2 |
LAB International Acquires Seyvika Pharma |
M&A |
2003/9/24 |
Ron Kaczorowski, President & COO |
Management |
2002/12/20 |
LAB International Closes Financing |
Financing |
2002/3/5 |
LAB International/1467523 Ontario Completes Financing |
Financing |
|
|
|
Akela Pharma Inc.
TSX: AKL; Frankfurt: LD9.F; XETRA: LD9.DE
formerly: LAB International Inc.
» To this firm page « (subscriber only)
3333 Côte Vertu, Suite 710
St-Laurent, QC
H4R 2N1
Tel: (450) 315-3330
Fax: (450) 315-3325
http://www.akelapharma.com
Sector - Biotechnology, Biopharmaceuticals
Business Description
Akela Pharma is a developer of therapeutics for the treatment of pain, and its PharmaForm subsidiary provides a range of innovative technologies in drug product development, manufacturing and analytical testing to the pharmaceutical and biotechnology industries.
|
|
Company News
|
Akela Pharm Announces Layoffs, Restructuring and Management Changes 2009/9/3
|
Akela Pharma Announces New Board of Directors 2009/6/26
|
Akela and Nventa Complete Merger 2009/5/22
|
LAB International Completes $12.3 Million PIPE Financing 2005/12/13
|
LAB International Acquires Danish CRO Scantox 2005/2/10
|
|
